Wells Fargo’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $476K | Buy |
283,099
+151,885
| +116% | +$221K | ﹤0.01% | 4667 |
|
|
2026
Q1 | $173K | Sell |
131,214
-182,800
| -58% | -$327K | ﹤0.01% | 4786 |
|
|
2025
Q4 | $587K | Buy |
314,014
+82,059
| +35% | +$158K | ﹤0.01% | 4369 |
|
|
2025
Q3 | $297K | Buy |
231,955
+44,092
| +23% | +$59.7K | ﹤0.01% | 4691 |
|
|
2025
Q2 | $233K | Buy |
187,863
+16,875
| +10% | +$19.5K | ﹤0.01% | 4686 |
|
|
2025
Q1 | $202K | Buy |
170,988
+7,834
| +5% | +$12K | ﹤0.01% | 4696 |
|
|
2024
Q4 | $299K | Buy |
163,154
+33,933
| +26% | +$66.2K | ﹤0.01% | 4531 |
|
|
2024
Q3 | $220K | Sell |
129,221
-19,416
| -13% | -$31.9K | ﹤0.01% | 4507 |
|
|
2024
Q2 | $204K | Buy |
148,637
+6,678
| +5% | +$13.5K | ﹤0.01% | 4514 |
|
|
2024
Q1 | $532K | Buy |
141,959
+41,421
| +41% | +$243K | ﹤0.01% | 3843 |
|
|
2023
Q4 | $986K | Buy |
100,538
+22,372
| +29% | +$183K | ﹤0.01% | 3440 |
|
|
2023
Q3 | $653K | Sell |
78,166
-48,333
| -38% | -$552K | ﹤0.01% | 3598 |
|
|
2023
Q2 | $1.68M | Buy |
126,499
+54,621
| +76% | +$664K | ﹤0.01% | 3051 |
|
|
2023
Q1 | $832K | Buy |
71,878
+35,212
| +96% | +$350K | ﹤0.01% | 3501 |
|
|
2022
Q4 | $300K | Buy |
36,666
+4,554
| +14% | +$39.2K | ﹤0.01% | 3947 |
|
|
2022
Q3 | $187K | Buy |
32,112
+4,289
| +15% | +$24.6K | ﹤0.01% | 4283 |
|
|
2022
Q2 | $123K | Sell |
27,823
-89,665
| -76% | -$545K | ﹤0.01% | 4529 |
|
|
2022
Q1 | $1.07M | Sell |
117,488
-98,451
| -46% | -$1.13M | ﹤0.01% | 3830 |
|
|
2021
Q4 | $4.42M | Buy |
215,939
+17,765
| +9% | +$429K | ﹤0.01% | 2698 |
|
|
2021
Q3 | $5.06M | Sell |
198,174
-39,389
| -17% | -$1.17M | ﹤0.01% | 2821 |
|
|
2021
Q2 | $8.31M | Buy |
237,563
+47,789
| +25% | +$1.39M | ﹤0.01% | 2379 |
|
|
2021
Q1 | $6.32M | Sell |
189,774
-139,252
| -42% | -$4.87M | ﹤0.01% | 2612 |
|
|
2020
Q4 | $8.54M | Buy |
329,026
+190,651
| +138% | +$3.24M | ﹤0.01% | 2224 |
|
|
2020
Q3 | $1.37M | Buy |
138,375
+15,314
| +12% | +$88.2K | ﹤0.01% | 3625 |
|
|
2020
Q2 | $423K | Buy |
123,061
+28,971
| +31% | +$98.6K | ﹤0.01% | 4446 |
|
|
2020
Q1 | $288K | Sell |
94,090
-246,455
| -72% | -$1.01M | ﹤0.01% | 4442 |
|
|
2019
Q4 | $1.75M | Buy |
340,545
+89,934
| +36% | +$457K | ﹤0.01% | 3453 |
|
|
2019
Q3 | $1.29M | Sell |
250,611
-48
| -0% | -$268 | ﹤0.01% | 3652 |
|
|
2019
Q2 | $1.52M | Buy |
250,659
+160,056
| +177% | +$1.12M | ﹤0.01% | 3563 |
|
|
2019
Q1 | $655K | Buy |
90,603
+6,947
| +8% | +$50.2K | ﹤0.01% | 4174 |
|
|
2018
Q4 | $619K | Buy |
83,656
+13,864
| +20% | +$87.8K | ﹤0.01% | 4205 |
|
|
2018
Q3 | $377K | Buy |
69,792
+668
| +1% | +$2.87K | ﹤0.01% | 4630 |
|
|
2018
Q2 | $246K | Sell |
69,124
-2,016
| -3% | -$5.59K | ﹤0.01% | 4916 |
|
|
2018
Q1 | $146K | Sell |
71,140
-70,571
| -50% | -$183K | ﹤0.01% | 5139 |
|
|
2017
Q4 | $374K | Sell |
141,711
-6,820
| -5% | -$23.9K | ﹤0.01% | 4597 |
|
|
2017
Q3 | $781K | Buy |
148,531
+2,297
| +2% | +$9.87K | ﹤0.01% | 4026 |
|
|
2017
Q2 | $520K | Sell |
146,234
-74,212
| -34% | -$299K | ﹤0.01% | 4197 |
|
|
2017
Q1 | $1.14M | Buy |
220,446
+87,308
| +66% | +$427K | ﹤0.01% | 3657 |
|
|
2016
Q4 | $506K | Buy |
133,138
+96,577
| +264% | +$702K | ﹤0.01% | 4196 |
|
|
2016
Q3 | $328K | Sell |
36,561
-891,937
| -96% | -$7.46M | ﹤0.01% | 4191 |
|
|
2016
Q2 | $6.53M | Buy |
928,498
+879,919
| +1,811% | +$8.04M | ﹤0.01% | 2128 |
|
|
2016
Q1 | $413K | Buy |
48,579
+5,054
| +12% | +$49.7K | ﹤0.01% | 3991 |
|
|
2015
Q4 | $572K | Sell |
43,525
-81,109
| -65% | -$728K | ﹤0.01% | 3845 |
|
|
2015
Q3 | $456K | Buy |
124,634
+106,179
| +575% | +$519K | ﹤0.01% | 3997 |
|
|
2015
Q2 | $106K | Sell |
18,455
-5,464
| -23% | -$31.6K | ﹤0.01% | 5024 |
|
|
2015
Q1 | $139K | Buy |
23,919
+6,663
| +39% | +$45.9K | ﹤0.01% | 4602 |
|
|
2014
Q4 | $135K | Buy |
17,256
+14,611
| +552% | +$93.5K | ﹤0.01% | 4616 |
|
|
2014
Q3 | $13K | Sell |
2,645
-1,447
| -35% | -$7.57K | ﹤0.01% | 5483 |
|
|
2014
Q2 | $25K | Buy |
+4,092
| New | +$20.5K | ﹤0.01% | 5282 |
|
|
2014
Q1 | – | Sell |
-750
| Closed | -$4K | – | 6018 |
|
|
2013
Q4 | $4K | Buy |
+750
| New | +$3.44K | ﹤0.01% | 5420 |
|
Other funds holding PACB
AIM
NAMA
Wells Fargo's PACB Position: Q2 2026 in Review
Wells Fargo increased its Pacific Biosciences (PACB) stake by 116% in Q2 2026, buying an estimated $221K and bringing the position to 283,099 shares worth $476K. The position accounts for ﹤0.01% of the portfolio, ranked #4667.
Wells Fargo first reported a position in PACB in Q4 2013 and has held it in 50 quarters since. The position peaked at $8.54M in Q4 2020. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- Wells Fargo held 283,099 shares of Pacific Biosciences worth $476K as of Q2 2026.
- Wells Fargo bought 151,885 Pacific Biosciences shares in Q2 2026, an estimated $221K.
- Pacific Biosciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4667 holding.
- Wells Fargo first reported a position in Pacific Biosciences in Q4 2013 and has held it in 50 quarters since.
- Wells Fargo's Pacific Biosciences position peaked at $8.54M in Q4 2020.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.